Compounds useful for inhibiting Chk1

A pharmaceutical composition comprising a compound which is (R)-[5-(2-methoxy-6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-[6-(piperidin-3-yloxy)-pyrazin-2-yl]-amine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.

A method of treating a cancer wherein the cancer is selected from the group consisting of colon cancer, and lung cancer, comprising administering to a patient in need thereof an effective amount of a compound which is (R)-[5-(2-methoxy-6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-[6-(piperidin-3-yloxy)-pyrazin-2-yl]-amine, or a pharmaceutically acceptable salt thereof.

A method of treating a cancer wherein the cancer is selected from the group consisting of colon cancer, and lung cancer, comprising administering to a patient in need thereof an effective amount of a compound which is (R)-[5-(2-methoxy-6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-[6-(piperidin-3-yloxy)-pyrazin-2-yl]-amine, or a pharmaceutically acceptable salt thereof, and ionizing radiation.

A method of treating a cancer wherein the cancer is selected from the group consisting of colon cancer and lung cancer comprising administering to a patient in need thereof an effective amount of a compound which is (R)-[5-(2-methoxy-6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-[6-(piperidin-3-yloxy)-pyrazin-2-yl]-amine, or a pharmaceutically acceptable salt thereof, and one or more chemotherapeutic agents wherein the one or more chemotherapeutic agents are selected from the group consisting of 5-fluorouracil, hydroxyurea, gemcitabine, methotrexate, pemetrexed, doxorubicin, etoposide, cisplatin, and Taxol®.